Histrelin

A gonadotropin-releasing hormone agonist used in hormone therapy

Chemical structure of Histrelin

Histrelin is a gonadotropin-releasing hormone (GnRH) agonist used primarily in the treatment of hormone-sensitive conditions such as prostate cancer and central precocious puberty. It is a synthetic analog of the naturally occurring GnRH, which plays a crucial role in the regulation of the pituitary gland and the release of gonadotropins.

Mechanism of Action

Histrelin functions by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. However, with continuous administration, it leads to downregulation of the GnRH receptors in the pituitary, resulting in decreased secretion of LH and FSH. This ultimately reduces the production of testosterone in males and estrogen in females, which is beneficial in conditions like prostate cancer and precocious puberty where hormone suppression is desired.

Medical Uses

Histrelin is primarily used in the following conditions:

Prostate Cancer

In the treatment of prostate cancer, histrelin is used to lower testosterone levels, which can help slow the growth of hormone-sensitive tumors. It is often part of androgen deprivation therapy (ADT).

Central Precocious Puberty

For children with central precocious puberty, histrelin helps delay the onset of puberty by suppressing the premature release of sex hormones. This can help in achieving a more typical timing of puberty and normal adult height.

Administration

Histrelin is administered as a subcutaneous implant, which provides a continuous release of the drug over a period of time, typically 12 months. This method of delivery ensures consistent hormone suppression without the need for daily medication.

Side Effects

Common side effects of histrelin include hot flashes, decreased libido, and mood changes. In children, it may cause temporary local reactions at the site of the implant. Long-term use can lead to decreased bone density, so monitoring is recommended.

Related Pages

• Gonadotropin-releasing hormone
• Prostate cancer
• Central precocious puberty
• Androgen deprivation therapy